Vyleesi Month-by-Month: What to Expect in the First 3 Months

What Bremelanotide Actually Does in the Body

Bremelanotide is not a hormone. It activates melanocortin 3 and 4 receptors in the central nervous system, areas linked to sexual motivation and reward. This mechanism sets it apart from flibanserin (Addyi), which works on serotonin and dopamine receptors and requires daily dosing.

The FDA granted bremelanotide approval on June 21, 2019, based on two randomized controlled trials known collectively as RECONNECT. The FDA prescribing information for Vyleesi specifies the approved population as premenopausal women only, distinguishing it clearly from HRT or testosterone-based approaches used in postmenopausal care [1].

How the Injection Mechanism Works

Each dose is 1.75 mg delivered via a single-use auto-injector into the abdomen or thigh. The injection is taken on demand, not daily. Peak plasma concentration occurs roughly 1 hour after injection, which aligns with the manufacturer-recommended 45-minute pre-activity window [1].

What "Central Activation" Means Practically

Because bremelanotide works on the brain rather than on genital tissue, patients should not expect an immediate physical response the way a vasodilator would produce. The effect is a shift in motivation and receptivity, not a mechanical one. Several patient reports on Drugs.com describe this as "a mental gear shift" rather than a physical sensation, which surprises some first-time users.

Month 1: High Side-Effect Burden, Variable Early Response

The first month is the hardest. Nausea is the dominant complaint, reported in 40.4% of participants in the pooled RECONNECT analysis (N=1,247) [2]. Flushing occurred in 20.3% and injection-site bruising in roughly 13%.

Nausea: The Make-or-Break Factor

Nausea typically peaks within 1 hour of injection and resolves within 2 to 4 hours. The RECONNECT investigators noted that nausea severity often decreases with repeated use, though the mechanism for this attenuation is not fully characterized [2].

Clinical practice at many HSDD-focused practices includes pre-medicating with 25 mg oral ondansetron (Zofran) 30 minutes before injection. The Vyleesi prescribing information itself recommends taking an anti-nausea medication before use [1]. Patients who skip this step in Month 1 report the worst experiences, a pattern that appears consistently across Drugs.com and Reddit community discussions.

A published analysis in the Journal of Sexual Medicine found that discontinuation rates due to nausea were highest in the first 8 weeks of use, after which tolerability improved substantially for those who remained on therapy [3].

Blood Pressure Fluctuations in Month 1

Bremelanotide produces a transient, dose-dependent decrease in blood pressure followed in some patients by a brief increase. Mean maximum decrease in systolic BP was approximately 6 mmHg within 12 hours of dosing in pharmacokinetic studies, per the FDA label [1]. Patients with cardiovascular disease or uncontrolled hypertension are contraindicated. Month-1 monitoring, especially for anyone with borderline BP, is appropriate clinical practice.

Realistic Efficacy Expectations at Week 4

Efficacy data from RECONNECT measured change from baseline in two co-primary endpoints: the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) and the desire domain of the Female Sexual Function Index (FSFI-D). At the end of the 24-week trial, statistically significant improvements appeared, but meaningful response at week 4 alone was not separately published [2].

Patients should enter Month 1 understanding that the drug is building a behavioral pattern of use, not producing a steady-state blood level the way a daily medication does.

Month 2: Tolerability Trends Improve, Efficacy Becomes Clearer

By week 5 through week 8, most patients who tolerated Month 1 report a noticeable reduction in nausea frequency. This is not universal. Approximately 18% of RECONNECT participants discontinued by end-of-trial due to adverse events, and a portion of those discontinuations occurred in weeks 5 to 10 [2].

Dialing In the Dosing Timing

Month 2 is when patients refine their personal timing. The 45-minute pre-injection window is an average. Some patients find 60 to 75 minutes produces a cleaner onset with less nausea overlap during activity. Others find the 45-minute window too long for spontaneous situations and plan a consistent weekly scenario instead.

The FDA label permits up to one dose per 24-hour period, with no specified monthly maximum, though cost is a practical limiter for most patients [1].

Hyperpigmentation: A Less-Discussed Month-2 Finding

Focal hyperpigmentation, particularly of the face, gums, and breasts, emerged in a subset of RECONNECT participants who used bremelanotide more than 8 times per month. The FDA label carries a specific warning about this finding, noting that it may not be reversible [1]. This is a point that community reviews on Reddit and Drugs.com rarely emphasize but that prescribers must discuss before patients ramp up frequency.

A 2019 review in Obstetrics and Gynecology summarized the hyperpigmentation signal and recommended limiting use to 8 or fewer doses per month in clinical practice [4].

Tracking Desire: Patient-Reported Outcomes in Month 2

The RECONNECT trial used the FSFI-D (desire subdomain, scored 1.2 to 6.0) as a co-primary endpoint. Baseline mean scores were approximately 2.0 in both arms. At 24 weeks, the bremelanotide arm showed a change of +0.6 versus +0.3 in placebo, a statistically significant but modest absolute difference [2]. Patients who kept a simple desire-frequency log in Month 2 are better positioned to assess whether their personal response exceeds placebo-level improvement.

Month 3: Staying or Stopping, How to Decide

Month 3 is the decision point. By 12 weeks, a patient has typically used the drug 4 to 15 times depending on frequency of sexual activity and willingness to use it for partnered versus solo scenarios. Side effects are at their most tolerable. Efficacy, or lack of it, is readable.

What a "Meaningful Response" Looks Like

The RECONNECT responder definition was a reduction of 2 or more points on the FSDS-DAO (a distress scale), plus an increase of at least 0.6 on the FSFI-D. Using this threshold, approximately 25% of bremelanotide users met both criteria versus roughly 17% in the placebo arm [2]. That leaves three-quarters of patients who may not meet the clinical responder definition, though some will still report subjective benefit that matters to them personally.

The HealthRX clinical team applies a structured 3-month decision framework for Vyleesi patients:

1. Month 1 checkpoint (Week 4). Did nausea become manageable with pre-medication? If nausea remains a 7/10 or higher after 3 doses with ondansetron pre-treatment, the risk-benefit calculus shifts toward discontinuation.
2. Month 2 checkpoint (Week 8). Is the patient logging at least one episode of increased desire per use, even if modest? A flat line across 6 or more uses suggests non-response.
3. Month 3 checkpoint (Week 12). Has FSFI-D or a validated personal scale moved at least 0.5 points, and has sexual distress (FSDS-DAO) decreased by at least 1 point? If neither is true, discontinuation is a reasonable clinical decision.

Stopping Bremelanotide: What Happens

There is no physiological dependence or withdrawal from bremelanotide. The drug has a half-life of approximately 2.7 hours and clears the system rapidly [1]. Patients who stop after 3 months return to their baseline desire levels; there is no documented rebound phenomenon in the literature.

A 2020 systematic review in Sexual Medicine Reviews evaluated long-term data from bremelanotide trials and found no evidence of tolerance, dependence, or worsening of HSDD after discontinuation [5].

Comparing Month-3 Outcomes: Bremelanotide vs. Flibanserin

The only other FDA-approved agent for HSDD is flibanserin (Addyi), a daily oral pill. Head-to-head trial data do not exist. An indirect comparison published in JAMA Internal Medicine noted that flibanserin produced a mean increase of 0.3 to 0.5 on the FSFI-D across trials, comparable to bremelanotide's 0.6-point gain, though study populations differed [6]. Patients who want daily background improvement rather than on-demand use should discuss flibanserin as an alternative.

Real Patient Experiences: What Aggregate Reviews Show

Structured clinical trial data captures efficacy but often misses the texture of daily experience. Across Drugs.com, Trustpilot, and Reddit forums including r/HSDD and r/WomensHealth, recurring themes emerge across the 3-month window.

The Nausea Narrative

Nearly every review in the first month mentions nausea as the primary obstacle. Patients who describe success consistently report two adaptations: taking an antiemetic beforehand and injecting in the thigh rather than the abdomen, which some users associate with less intense nausea onset. Neither of these adaptations has been formally studied in a randomized fashion, but they align with general pharmacokinetic principles about subcutaneous absorption rates.

The "It Works But Is It Worth It" Pattern

By Month 3, reviews split into two camps. One group reports genuine, repeatable desire improvement and accepts residual nausea as a tradeoff. The other group finds the side-effect-to-benefit ratio unfavorable, particularly given the cost. Out-of-pocket cost without insurance coverage runs approximately $800, $900 per month. Palatin Technologies, the manufacturer, offers a savings card that may reduce cost for eligible patients, but insurance coverage remains inconsistent.

Injection Confidence Builds Over Time

Early reviews often cite anxiety about self-injection as a barrier. By Month 2, the vast majority of continuing patients describe the auto-injector as straightforward. The device design was studied in a human factors trial cited in the FDA approval package, and administration errors were minimal after one training session [1].

Who Should Not Use Bremelanotide

The contraindications are specific and clinically significant.

Cardiovascular Contraindications

Bremelanotide is contraindicated in patients with known cardiovascular disease, uncontrolled hypertension (defined as systolic above 165 mmHg or diastolic above 105 mmHg at baseline in trial entry criteria), or high cardiovascular risk. The transient BP effect is small on average but unpredictable at the individual level [1].

A pharmacovigilance review posted by the FDA's MedWatch system identified a small number of serious cardiovascular adverse event reports post-approval, though causality assessment was complicated by underlying patient comorbidities [1].

Postmenopausal Women

Bremelanotide is not approved for postmenopausal women. The RECONNECT trials enrolled only premenopausal women aged 22 to 70 (mean age 38). The FDA label explicitly restricts the indication, and data on safety and efficacy in postmenopausal women are not available from controlled trials [1].

The Endocrine Society clinical practice guideline on female sexual dysfunction recommends that postmenopausal patients with low desire be evaluated for androgen deficiency and hormone status before any pharmacological intervention [7].

Pregnancy and Lactation

Bremelanotide is pregnancy category X equivalent. Animal studies showed fetal harm. Patients trying to conceive should not use this drug. Data on passage into breast milk are absent; the label recommends avoiding use during lactation [1].

Dosing Optimization: Practical Clinical Notes

Getting the Timing Right

The 45-minute pre-injection recommendation comes from pharmacokinetic modeling of time-to-peak plasma concentration [1]. Patients in spontaneous sexual relationships often find this logistically awkward. A practical workaround, used in clinical practice but not formally studied, is to associate dosing with a consistent preparatory activity (bathing, a shared meal) that naturally occurs 45 to 60 minutes before intimacy.

Rotating Injection Sites

The label permits abdomen or thigh administration. Rotating sites within each region helps prevent local bruising and induration, which were reported in approximately 13% of RECONNECT participants [2]. Patients who develop persistent injection-site changes should have those areas assessed before continuing use.

Antiemetic Pre-Treatment Dosing

Ondansetron 4 to 8 mg orally 30 minutes before injection is the most commonly recommended regimen in clinical practice. Some clinicians prefer promethazine 12.5 mg. No head-to-head comparison of antiemetic strategies for bremelanotide has been published, but a pharmacological rationale exists for 5-HT3 antagonism given the serotonergic component of nausea from melanocortin activation [3].

Key Clinical Guideline Positions on Bremelanotide

The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care consensus in 2019 that positioned bremelanotide as a second-line option after addressing relationship, psychological, and hormonal contributors to HSDD [8]. The guideline states, "Bremelanotide may be considered when non-pharmacological approaches are insufficient, with appropriate patient selection and counseling regarding the side-effect profile" [8].

The American College of Obstetricians and Gynecologists (ACOG) echoes this positioning, recommending shared decision-making that includes discussion of the modest absolute effect sizes and the nausea burden before prescribing [9].

The 3-Month Cost-Benefit Calculation

At approximately $850 per month and a clinical responder rate of roughly 25%, the number needed to treat (NNT) above placebo in RECONNECT was approximately 12 using the dual responder criterion [2]. That figure contextualizes the decision: for every 12 patients who use bremelanotide for 24 weeks, approximately 1 benefits in a way that clearly exceeds placebo.

That NNT is not an argument against the drug for patients who respond. For the subset who respond, the benefit is real and meaningful. The number is a calibration tool for setting expectations before Month 1 begins.

A 2021 pharmacoeconomic analysis published in Value in Health found that bremelanotide's cost-effectiveness ratio exceeded conventional thresholds at full out-of-pocket cost but fell within acceptable ranges when manufacturer discounts reduced monthly cost below $400 [10].